Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Penn Update on Novel Therapies for Higher Risk MDS: What Is the Role of Pevonedistat & Sabatolimab? Is Venetoclax an Option? Should We Consider Magrolimab? Is Enasidenib Effective in IDH2 MDS?
Comments 0
Login to view comments.
Click here to Login
